Jazz Pharmaceuticals (JAZZ) Q3 2026 earnings summary

Executive summary

• Record Q3 revenue of $1,243.0M, up 10% YoY; Oncology grew 35% and Xywav 12%, supporting raised FY26 revenue guidance of $4.775B-$4.85B.

• Ziihera’s first-line HER2-positive GEA launch and the Actio acquisition of ABS-1230 added commercial and pipeline growth drivers; zanidatamab peak sales potential is $3B-$5B.

Financial highlights

• Q3 revenue was $1,243.0M versus $1,126.1M in Q3 2025; nine-month revenue rose 15% to $3,520.2M.

• Q3 GAAP net loss was $483.4M, or $7.48 per diluted share; adjusted net loss was $250.8M, or $3.88 per diluted share.

• Q3 operating loss was $413.4M; nine-month operating income was $171.4M versus a $684.8M loss in 2025.

• Nine-month net income was $2.5M, including a $122.8M PRV-sale gain; prior-year results included litigation costs and a $206M deferred-tax benefit.

Outlook and guidance

• FY26 revenue guidance rose to $4.775B-$4.85B from $4.6B-$4.75B; rare sleep revenue guidance is $2.125B-$2.175B.

• Adjusted gross margin guidance is 90.5%-91.5%; adjusted SG&A is $1.33B-$1.37B, adjusted R&D $725M-$775M, and adjusted tax rate 19.5%-21.5%.

• Xywav is expected to grow low double digits to low teens; combined rare oncology and epilepsy revenue is expected to grow at double digits.

• Milestones include initial ABS-1230 data in 4Q26, ACTION results in 1H27, Epidiolex capsule PDUFA on April 16, 2027, and EmpowHER-303 data in late 2027 or early 2028.